Market Intelligence, Clinical Progress, and High-Purity Reagents for Tumor Angiogenesis and Solid Tumor Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLEC14A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLEC14A ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View CLEC14A Products |
| Gene Delivery | CLEC14A Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based assays. |
View CLEC14A Products |
| Benchmark Ab | Anti-CLEC14A Recombinant Antibody Recombinant positive control derived from benchmark clinical/preclinical clones. |
View CLEC14A Products |
| Validator | CLEC14A siRNA Set For knockdown verification and target specificity validation. |
View CLEC14A Products |
| Related Target A | CD93 Group 14 C-type lectin family member. Crucial for off-target counter-screening and specificity profiling. |
View CD93 Products |
| Related Target B | ANTXR1 Tumor Endothelial Marker 8 (TEM8). Synergistic target for tumor vascular disruption strategies. |
View ANTXR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation | Human, Mouse, and Cynomolgus CLEC14A ortholog proteins available with >95% purity for robust cross-reactivity screening |
| Subfamily off-target screening | Homolog panel proteins (CD93, CD248) strictly verified by mass spectrometry to eliminate false-positive leads |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration |
| False Positives | Validated siRNA sets included for target-specific knockdown and assay validation |
Live CLEC14A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLEC14A therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapies. As first-generation therapies targeting tumor angiogenesis reach the clinic, the next wave of R&D is targeting the selective destruction of tumor-associated endothelial cells while sparing healthy vasculature.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Biotech Startups, Academic Consortia | Advanced Solid Tumors | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| CAR-T | Cancer Research UK, Clinical Stage Biopharma | Glioma, Triple-Negative Breast Cancer | Cell-based Activation & Cytotoxicity Validation (Need Lentivirus for stable cell lines) |
| Bispecific Ab | Global Biopharma Cooperatives | Neovascularized Solid Tumors | Dual-Target Binding Assays (Need high-purity CLEC14A and VEGFR2/CD93 antigens) |